Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Braveheart Bio, Inc. - Common Stock (NQ:BRVE)

21.12 -0.15 (-0.71%)
Delayed Quote Updated: 3:37 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Braveheart Bio, Inc. - Common Stock

News headline image
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
From Braveheart Bio, Inc.
Via GlobeNewswire
News headline image
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
From Braveheart Bio, Inc.
Via GlobeNewswire
News headline image
Braveheart Bio to Participate in Cantor Global Healthcare Conference
From Braveheart Bio, Inc.
Via GlobeNewswire
News headline image
Insiders Are Betting Big on These 3 Healthcare Stocks ↗
Insiders are buying shares of Braveheart Bio, BlossomHill Therapeutics and Elanco, three health care stocks with differing risk profiles, analyst ratings, and pipeline catalysts ahead. 
Via MarketBeat
Topics Initial Public Offering
News headline image
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success? ↗
Option exercise expands executive's long-term equity stake to 612,251 shares, now valued at $18.37 million based on August 7 market close. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors? ↗
Insider exercise expanded his direct stake by 16% to 609,519 shares, bringing total beneficial ownership to ~760,000 shares valued at $22.8 million. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors? ↗
Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Braveheart Bio, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.